Business
Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (TNBC)
LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA) Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated with neutropenia and asthenia as the most common ...
About this update from Cantargia Ab
[{"type":"text","content":"LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)","length":70,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated with neutropenia and asthenia as the most common side effects","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"The primary endpoint, overall response rate (ORR),was similar in the nadunolimab plus carboplatin/gemcitabine treated group and the carboplatin/gemcitabine reference group","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":363,"olType":false},{"type":"text","content":"TRIFOUR is an exploratory open label randomized Phase 1b/2 clinical study conducted by the Spanish Breast Cancer Group (GEICAM).The objective is to evaluate early signals of efficacy of Cantargia's IL1RAP antibody nadunolimab in TNBC, with unconfirmed ORR as primary endpoint. The ORR was 40% in the Ph2 study in the nadunolimab plus GC treated patients. As reference, the ORR in the GC group was 43%. Subgroup analyses of the data are ongoing.","length":448,"tagName":"p"},{"type":"text","content":"The tolerability of the combination was acceptable and in line with previous trials combining nadunolimab and chemotherapy. Most common side effects in this trial were neutropenia and asthenia with no notable differences between the two study arms.","length":248,"tagName":"p"},{"type":"text","content":""TNBC is a heterogeneous and difficult to treat disease, with a high unmet medical need. We welcome the efforts to explore new treatments and appreciate the learnings we are making from the TRIFOUR study. We now await the outcome of further analyses from the study, including overall survival," said Dr. Eva Carrasco, CEO of GEICAM.","length":342,"tagName":"p"},{"type":"text","content":""We are pleased to have the opportunity to collaborate with GEICAM and explore nadunolimab in the TNBC indication. While the preliminary ORR results of the Phase 2 part of the TRIFOUR trial do not match those obtained in the Phase 1b part of the trial, the study continues and we will now await the mature survival data." said Damian Marron, interim CEO of Cantargia. "Following the signing of our CAN10 agreement earlier this week, we will...